Task Force 4: Inpatient Management of Patients with MCSD - The ...

60. McGrady A, McGinnis R, Badenhop D, Bentle M, Rajput M. Effects of depression and anxiety
on adherence to cardiac rehabilitation. J Cardiopulm Rehabil Prev. 2009;29(6):358-364.
61. Humphrey R. Exercise physiology in patients with left ventricular assist devices. J Cardiopulm
Rehabil. 1997;17(2):73-75.
62. Goodlin SJ, Hauptman PJ, Arnold R et al. Consensus statement: Palliative and supportive care
in advanced heart failure. J Card Fail. 2004;10(3):200-209.
63. Rizzieri AG, Verheijde JL, Rady MY, McGregor JL. Ethical challenges with the left ventricular
assist device as a destination therapy. Philos Ethics Humanit Med. 2008;3:20.
64. Bramstedt KA, Wenger NS. When withdrawal of life-sustaining care does more than allow
death to take its course: the dilemma of left ventricular assist devices. J Heart Lung
Transplant. 2001;20(5):544-548.
65. Bramstedt KA, Nash PJ. When death is the outcome of informed refusal: dilemma of rejecting
ventricular assist device therapy. J Heart Lung Transplant. 2005;24(2):229-230.
66. Wiegand DL, Kalowes PG. Withdrawal of cardiac medications and devices. AACN Adv Crit Care.
2007;18(4):415-425.
67. Grady KL, Meyer PM, Mattea A et al. Change in quality of life from before to after discharge
following left ventricular assist device implantation. J Heart Lung Transplant. 2003;22(3):322-
333.
68. Wilson SR, Givertz MM, Stewart GC, Mudge GH, Jr. Ventricular assist devices the challenges of
outpatient management. J Am Coll Cardiol. 2009;54(18):1647-1659.
69. Genovese EA, Dew MA, Teuteberg JJ et al. Early adverse events as predictors of 1-year
mortality during mechanical circulatory support. J Heart Lung Transplant. 2010;29(9):981-988.
70. Mehra MR, Uber PA, Uber WE, Scott RL, Park MH. Allosensitization in heart transplantation:
implications and management strategies. Curr Opin Cardiol. 2003;18(2):153-158.
71. Meyer AL, Malehsa D, Bara C et al. Acquired von Willebrand syndrome in patients with an axial
flow left ventricular assist device. Circ Heart Fail. 2010;3(6):675-681.
72. Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von
Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left
ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009;53(23):2162-2167.
73. Crow S, John R, Boyle A et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and
pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg. 2009;137(1):208-215.
74. Crow S, Chen D, Milano C et al. Acquired von Willebrand syndrome in continuous-flow
ventricular assist device recipients. Ann Thorac Surg. 2010;90(4):1263-1269.
75. Demirozu ZT, Radovancevic R, Hochman LF et al. Arteriovenous malformation and
gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart
Lung Transplant. 2011;30(8):849-853.
76. Genovese EA, Dew MA, Teuteberg JJ et al. Incidence and patterns of adverse event onset
during the first 60 days after ventricular assist device implantation. Ann Thorac Surg.
2009;88(4):1162-1170.
77. Pagani FD, Miller LW, Russell SD et al. Extended mechanical circulatory support with a
continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54(4):312-321.
78. Holman WL, Kormos RL, Naftel DC et al. Predictors of death and transplant in patients with a
mechanical circulatory support device: a multi-institutional study. J Heart Lung Transplant.
2009;28(1):44-50.
79. Kirklin JK, Naftel DC, Kormos RL et al. Second INTERMACS annual report: more than 1,000
primary left ventricular assist device implants. J Heart Lung Transplant. 2010;29(1):1-10.
45